BioGenCell is a clinical stage, biotechnology startup company, developing a disruptive biotechnology platform that combines the power of immunology and stem cell therapies to transform patient's blood into a lifesaving cellular treatment.
Our technology enables a long lasting, safe, effective, and accessible cellular therapy for the treatment of various vascular diseases which are the #1 death and disability cause in the world.
Our leading product BCG101, is designed to treat CLI (Critical Limb Ischemia), a chronic condition typical of diabetic and smoking populations, leading to amputation and death.
We have conducted FIH (First In Human) clinical trials with very promising results. Patients experience wound healing, walking ability improvement, reduction of pain and a major improvement in their quality of life a year after the treatment.
Tel: (972) 9-8609598